Based in Australia, Medlab Clinical is developing therapeutics using its proprietary delivery platform NanoCelle. Its most advanced programme is in cancer pain management with lead drug candidate NanaBis, a medicinal cannabis product for cancer-related bone pain. It is also developing a synthetic THC/CBD analogy of NanaBis.
More Medlab Clinical content >Investment summary
Medlab’s proprietary platform, NanoCelle, is a patented nanomicellar formulation that can improve the delivery of drugs. Medlab’s lead product is NanaBis, a combination of THC and CBD (1:1) cannabinoids encapsulated in NanoCelle particles, which enable a convenient buccal spray formulation. A recent breakthrough was Medlab’s announcement that it had successfully produced a synthetic version of NanaBis, which will allow it to move away from a botanical extract. Once the product reformulation is completed, NanaBis will re-enter clinical development (potentially Phase III) as a fully synthetic, non-opioid pain relief drug aimed at a vast market. Using NanoCelle delivery technology, Medlab is also expanding beyond cannabinoids and is pursuing several small and large molecule programmes (including a non-invasive mRNA COVID-19 vaccine).
Y/E Jun |
Revenue (A$m) |
EBITDA (A$m) |
PBT (A$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
---|---|---|---|---|---|---|
2020A | 5.8 | (12.3) | (13.5) | (5.9) | N/A | N/A |
2021A | 8.1 | (11.4) | (12.4) | (4.2) | N/A | N/A |
2022E | 8.0 | (11.7) | (12.7) | (3.7) | N/A | N/A |
2023E | 10.4 | (9.9) | (11.0) | (3.2) | N/A | N/A |
Industry outlook
There is a growing consensus in the medical community that medicinal cannabis has a place in chronic pain management. With the opioid crisis unravelling, we believe support for non-opioid pain killers from various stakeholders will only grow.
Last updated on 23/05/2022Content on Medlab Clinical






Sector |
---|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
---|---|
Forecast net cash (A$m) | 0.7 |
Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
*% relative to local index |
Key management |
|
---|---|
Sean Hall | CEO |